Alzheimer's Disease Trial, By Invitation NCT04042532 Sponsor: Chang Gung Memorial Hospital Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, By Invitation

NCT04042532
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have a confirmed diagnosis of Alzheimer's disease dementia, based on established international medical guidelines (the NIA-AA criteria).
  • People whose dementia symptoms began before the age of 65.
  • People aged between 50 and 75 years old (this applies to both the patient group and the healthy comparison group).
  • People whose dementia is at a mild to moderate stage, based on a standard rating scale called the Clinical Dementia Rating (CDR), with a score between 0.5 and 2.
  • People in the healthy comparison group who have normal thinking and memory abilities, shown by a memory test score of 24 or above (MMSE) and a CDR score of 0.
  • People (and their family members) who are willing and able to give their agreement to take part in the trial.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a confirmed diagnosis of epilepsy or a history of seizures.
  • People who have had a significant brain or nervous system condition that has affected how the brain looks or works, such as a stroke, a head injury, or a brain tumour.
  • People who have a significant or unstable medical condition affecting organs such as the kidneys, liver, lungs, heart, or metabolism.
  • People who have misused or been dependent on alcohol or other substances in the past year, or who have a long history of substance misuse.
  • People who are currently pregnant or breastfeeding.
  • People who are unable to safely have an MRI, TMS, or PET scan — for example, those who have had brain aneurysm surgery, or who have a pacemaker, mechanical heart valves, a cochlear implant, or other metal devices in the body that are not safe to use in an MRI scanner.
  • People who have had an allergic reaction to the scanning substances used in this trial (18F-florbetapir or 18F-FDG).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 18 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
3 January 2020
Est. completion
30 June 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Change from baseline MMSE total scores immediately after TBS intervention; Change from baseline MMSE total scores 4 weeks after TBS intervention; Change from baseline ADAS-Cog total scores immediately after TBS intervention; Change from baseline ADAS-Cog total scores 4 weeks after TBS intervention

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 18 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov